Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
复制标题
在肝脏恶性肿瘤射频消融过程中，热门部署的脂质体阿霉素的第一阶段研究。
DOI：
10.1016/j.jvir.2011.10.018
复制
发表时间：
2012-02
影响因子：
2.9
通讯作者：
Libutti, Steven K.
中科院分区：
文献类型：
--
作者：
Wood, Bradford J.;Poon, Ronnie T.;Locklin, Julia K.;Dreher, Matthew R.;Ng, K. K.;Eugeni, Michelle;Seidel, Geoffrey;Dromi, Sergio;Neennan, Ziv;Kolf, Michael;Black, Christopher D. V.;Prabhakar, Raj;Libutti, Steven K.
A phase I dose escalation study was performed with systemically delivered lyso-thermosensitive liposomal doxorubicin (LTLD) (Celsion Corp., Columbia, MD). The primary objectives were to determine the safe maximum tolerated dose (MTD), pharmacokinetic (PK) properties, and dose limiting toxicity (DLT) of LTLD during this combination therapy. Subjects eligible for percutaneous or surgical RFA with primary (n=9) or metastatic (n=15) tumors of the liver, with lesions 4 or less in number and up to 7 cm in diameter were included. RFA was initiated 15 minutes after starting a 30 minute intravenous LTLD infusion. Dose levels between 20 and 60 mg/m2 were evaluated. MRI, PET and CT scans were performed at predetermined intervals pre and post-treatment until evidence of recurrence, administration of additional antitumor treatment, or a total of 3 years. DLT criteria were met at 60 mg/m2, and the MTD was defined as 50 mg/m2. RFA was performed during the peak of the plasma concentration-time curve, in an effort to yield maximal drug deposition. LTLD produced reversible, dose-dependent neutropenia and leukopenia. LTLD can be safely administered systemically at the MTD (50 mg/m2) in combination with RFA, with limited and manageable toxicity. Further evaluation of this agent combined with RFA is warranted to determine its role in the management of liver tumors.
登录
查看更多内容
影响因子：
45.3
作者：
Berber, E;Pelley, R;Siperstein, AE
通讯作者：
Siperstein, AE
影响因子：
19.7
作者：
Livraghi, T;Solbiati, L;Goldberg, SN
通讯作者：
Goldberg, SN
DOI：
10.1007/s00464-004-8815-z
发表时间：
2005-05-01
影响因子：
3.1
作者：
Berber, E;Rogers, S;Siperstein, A
通讯作者：
Siperstein, A
影响因子：
5
作者：
Goldberg, SN;Kamel, IR;Raptopoulos, V
通讯作者：
Raptopoulos, V
DOI：
10.1093/jnci/djk005
发表时间：
2007-01-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Ponce, Ana M.;Viglianti, Benjamin L.;Dewhirst, Mark W.
通讯作者：
Dewhirst, Mark W.